All things Alzheimer’s: This week’s news on the most common form of dementia

While the start of Spring may not have brought on the warmer weather that we were all hoping for, it certainly brought in a wave of attention for Alzheimer’s disease (AD). There seemed to be no shortage of exciting and thought-provoking AD news this week so the IOA decided to highlight some of the top stories here.

| 2015 Alzheimer’s Disease Facts and Figures Report

First up, the Alzheimer’s Association recently released their official 2015 Screen Shot 2015-03-26 at 11.58.48 AMAlzheimer’s Disease Facts and Figures Report, a statistical resource for the most current knowledge on all aspects of Alzheimer’s disease. This report includes information on Alzheimer’s prevalence, mortality and morbidity, caregiving, and costs. In addition, this year’s report includes special coverage on disclosing the diagnosis of AD to patients and their family members, which is an issue that has sparked quite a bit of conversation this week as well.

| Disclosing the Diagnosis of Alzheimer’s Disease

According to new findings from research conducted by the Alzheimer’s Association, an estimated 55% of Alzheimer’s patients do not know their diagnosis. They are typically treated without being told their condition until the disease has progressed to a much more advanced stage. Representatives from the Alzheimer’s Association explain that the biggest problem with this, other than overriding a patient’s general right to be in-the-know, is that it is taking away the patient’s ability to make certain life decisions and plan for their future or to choose to participate in potentially beneficial clinical trials while they still can.

“Doctors commonly cite fear of causing emotional distress as one of the main reason they fail to disclose an Alzheimer’s diagnosis,” quoted the recent CBS News article covering the story, which also listed “uncertainty about their diagnosis, insufficient time to fully discuss treatment options and support services, a lack of support services, and the general stigma that surrounds Alzheimer’s,” as the other reasons given by doctors for not disclosing the diagnosis.

For the full CBS News article, click here.

| New clinical trial raises hope for possible treatment of Alzheimer’s Disease

Recent news of a “game changing” clinical trial for Alzheimer’s treatment highlights the ongoing A4 Study that is testing whether the drug Solanezumab can slow the progression or even prevent Alzheimer’s disease.

Screen Shot 2015-03-26 at 2.53.24 PMThe clinical trial, which is being offered at several different sites across the country including the University of Pennsylvania, is targeting patients who have not yet experienced symptoms related to AD, but whose brain scans indicate they will likely develop the disease in the future. The scans reveal that these patients have a buildup of amyloid plaque, which is one of the proteins believed to cause Alzheimer’s disease, in addition to tau tangles. The hope is that this drug will kill the amyloid before the amyloid can kill the brain cells, resulting in the disease.

For the full CBS News article, click here.

For more information on the A4 Study, click here.

| In other news…

While not directly related to Alzheimer’s disease, the coverage on the A4 Study also brings up the conversation about another recent breakthrough in the realm of neurodegenerative diseases right here at the University of Pennsylvania. Penn Medicine researcher, Corey McMillan, research assistant professor of Neurology in the Penn Frontotemporal Degeneration Center, and his colleagues, have identified a new potential drug target to protect against Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD). They have found that hypermethylation, the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of all patients with ALS and FTD, can serve as a protective barrier preventing the development of these diseases.

For the full Penn Medicine News Release, click here.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s